HOUSTON / Feb 20, 2025 / Business Wire / U.S. Physical Therapy, Inc. (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, announced that it will report its financial results for the fourth quarter and year ended December 31, 2024, on Wednesday, February 26, 2025, after the stock market closes, with the conference call to follow the next morning, on Thursday, February 27, 2025.
| Conference Call | Date: | Thursday, February 27, 2025 |
Time: | 10:30 am Eastern/9:30 am Central | |
Dial-In Number: | (800) 445-7795 Primary or | |
| (785) 424-1699 Alternate | |
Conference ID: | USPHQ424 | |
(In order to join this conference call, you will be required to provide the Conference ID listed above) | ||
| To participate, please call in 15 minutes prior to start time. | ||
To listen to the live call, please go to www.usph.com and click on conference calls under the Investor Relations section. Please go to the website 15 minutes early to register, download and install any necessary audio software. If you are unable to listen live, a playback of the conference call can be accessed until May 28, 2025, at U.S. Physical Therapy’s website.
About U.S. Physical Therapy, Inc.
Founded in 1990, U.S. Physical Therapy, Inc. owns and/or manages 772 outpatient physical therapy clinics in 43 states. USPH clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. USPH also has an industrial injury prevention business which provides onsite services for clients’ employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments.
More information about U.S. Physical Therapy, Inc. is available at www.usph.com. The information included on that website is not incorporated into this press release.
| Last Trade: | US$67.45 |
| Daily Change: | -1.00 -1.46 |
| Daily Volume: | 14,743 |
| Market Cap: | US$1.020B |
March 03, 2025 February 26, 2025 December 02, 2024 November 12, 2024 November 05, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
